New Test Launch Veracyte's upcoming launch of ClearLab, a test for muscle-invasive bladder cancer, in 2026 presents a potential sales opportunity for targeting healthcare providers looking for innovative diagnostic solutions.
Investment Inflows Recent investments from firms like Quest Partners LLC and Jennison Associates LLC in Veracyte indicate growing confidence from investors, signaling a potential avenue for partnership or collaboration opportunities.
Acquisition Expansion Through the recent acquisition of C2i Genomics, Veracyte has broadened its portfolio, opening up possibilities for cross-selling diagnostic tests and exploring new channels for revenue generation.
Revenue Growth Veracyte's revenue range of $100M - $1B signals significant market presence and financial stability, making it an attractive prospect for businesses seeking to align with a successful and established player in the biotechnology research industry.
Competitive Position Among similar companies like Illumina, Foundation Medicine, and Guardant Health, Veracyte's unique diagnostic offerings position it as a competitor to watch, presenting opportunities for strategic partnerships or differentiation strategies to capture market share.
Veracyte, Inc. uses 8 technology products and services including theTradeDesk, Hotjar, MySQL, and more. Explore Veracyte, Inc.'s tech stack below.
| Veracyte, Inc. Email Formats | Percentage |
| first.last@veracyte.com | 53% |
| first@veracyte.com | 44% |
| flast@veracyte.com | 3% |
| last@veracyte.com | 0% |
Biotechnology ResearchCalifornia, United States501-1000 Employees
Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our growing menu of diagnostic tests answers important clinical questions to help patients avoid risky, costly procedures and interventions, and accelerate time to appropriate treatment.
Company Overview
Funding & FinancialsVeracyte, Inc. has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2013 in the amount of $65Mas a initial public offering (IPO).
Veracyte, Inc.'s revenue is in the range of $100M$1B
Funding & FinancialsVeracyte, Inc. has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2013 in the amount of $65Mas a initial public offering (IPO).
Veracyte, Inc.'s revenue is in the range of $100M$1B
Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.
1-888-653-2347 
support@leadiq.com